Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386775 · ClinicalTrials.gov registry record
Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation
A clinical trial of Hypohidrotic Ectodermal Dysplasia, sponsored by Edimer Pharmaceuticals.
- Completed
- Registry status
- 64
- Enrollment target
- 1
- Study location
NCT01386775: Completed study of Hypohidrotic Ectodermal Dysplasia, sponsored by Edimer Pharmaceuticals.
NCT01386775 is a study of Hypohidrotic Ectodermal Dysplasia that has completed, run by Edimer Pharmaceuticals. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01386775, a study of Hypohidrotic Ectodermal Dysplasia, has completed, sponsored by Edimer Pharmaceuticals.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study in affected Hypohidrotic Ectodermal Dysplasia (HED) males and unaffected male controls, age 1 year and up, will use minimally invasive devices to image sweat ducts in intact skin, to measure stimulated sweat rate, and in a subset of subjects to collect clipped scalp hair samples for RNA analysis. This study is descriptive in nature and is intended to assess the ability to use innovative approaches to generate data from subjects over a wide age spectrum, with particular emphasis on phenotype variability between male siblings (same mutation).
Primary Outcome
Day 1
Conditions Studied
Study Locations (1)
Illinois
- Hilton Garden Inn St. Louis Shiloh/O'Fallon - O'Fallon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-09 |
What the finished NCT01386775 record still lists
NCT01386775 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 1 condition, with Hypohidrotic Ectodermal Dysplasia appearing as the primary indexed condition, and to 0 interventions.
NCT01386775 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01386775 about?
NCT01386775 is a clinical study titled "Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation". This study in affected Hypohidrotic Ectodermal Dysplasia (HED) males and unaffected male controls, age 1 year and up, will use minimally invasive devices to image sweat ducts in intact skin, to measure stimulated sweat rate, and in a subset of subjects to collect clipped scalp hair samples for RNA a...
What is the current status of trial NCT01386775?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2011-06. Estimated completion is 2011-09.
What conditions does trial NCT01386775 study?
This clinical trial studies the following conditions: Hypohidrotic Ectodermal Dysplasia.
Who is sponsoring clinical trial NCT01386775?
This trial is sponsored by Edimer Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01386775 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia